Argenx Hosts R&D Webinar on Autoimmune Myositis Treatments
Argenx, an immunology specialist, is hosting a webinar today dedicated to its research and development in autoimmune myositis. The event brings together the company's scientific leadership and external experts, highlighting its commitment to this therapeutic field.
The webinar, titled 'R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis', is scheduled for Tuesday, June 23 at 2:00 PM (New York time). Argenx will present its work on neonatal Fc receptor (FcRn) blockers, its flagship technology developed to treat severe autoimmune diseases. The presentation explores the potential of this approach applied to myositis, a group of inflammatory diseases affecting the muscles.
Expertise Gathered in Rheumatology and Neurology
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Argenx's scientific leadership is joined by three recognized experts: Avery LaChance (Associate Professor of Dermatology at Harvard Medical School, Director of the Connective Tissue Disease Clinic), Arjun Seth (Assistant Professor in Neurology (Neuromuscular Diseases) at Northwestern University Feinberg School of Medicine), and Rohit Aggarwal (Professor at the University of Pittsburgh, Co-Director of the Myositis Center at UPMC). This lineup underscores the involvement of multiple medical specialties in exploring this therapeutic indication. The event is part of a series of communications highlighting the group's R&D portfolio in immunology and the clinical data of its candidates. A live broadcast will be available on Argenx's Investors site, along with a recording preserved for one year.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1.3MD€
Net income: 366M€
Guidance from the release
argenx continue de livrer un impact significatif pour les patients.
Argentx affiche une croissance de 63% par rapport à l'année précédente.
Risks mentioned
Les résultats peuvent varier en fonction des incertitudes liées aux essais cliniques.
L'impact des lois et règlements gouvernementaux pourrait affecter les activités.
Opportunities identified
VYVGART pourrait devenir la première thérapie approuvée dans les populations gMG.
Lancement d'une étude pour le candidat pipeline empasiprubart.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
